The main conclusion is well supported because the primary endpoint was clearly negative in both trials. How does this work fit with the existing evidence
That is, the group that initially got Eriomin took it for 12 weeks, then stopped for a two-week washout period, before taking the placebo for 12 weeks and vice-versa for the other group (placebo first, then Eriomin)
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
These alterations indicate enhanced glutamatergic neurotransmission and synaptic strengthening, which are hallmark features of central sensitization
It's designed to work in harmony with the body's own signaling mechanisms to support repair, balance, and resilienceparticularly in tissues like the gut, joints, and muscles
.webp)
